SCH 31742
Latest Information Update: 20 Jul 2001
At a glance
- Originator Schering-Plough
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Jul 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 22 Oct 1997 Preclinical development for Cancer in USA (Unknown route)
- 29 Sep 1997 New profile